Why a drug-name list is not enough for targeted therapy review
Targeted cancer treatment acts on particular molecular features, and biomarker findings can help clinicians assess potential treatment options. A list such as 'carboplatin, pemetrexed, osimertinib' tells a reviewer almost nothing about whether a targeted option was appropriate, whether it worked, or why it stopped. The receiving team needs the reasoning behind each line.
For an overseas patient asking a Chinese hospital to review targeted therapy options, the practical decision is narrower than 'which drug should I take'. It is whether this centre can assess the case at all, and whether it can continue or adjust treatment and monitoring without a gap. That decision depends on the quality of the previous-treatment record, not on the number of drug names.
A useful record answers four questions for each prior line: what molecular feature was being targeted, what was given, what happened, and why it ended. Without those four, a clinician may have to ask for clarification before any opinion is possible, which slows the review.
Describe each previous treatment as a short structured entry
Write one entry per treatment line rather than a chronological narrative. Each entry should name the drug or regimen exactly as it appears on the prescription or discharge summary, including the generic name and, where relevant, the brand. Then state the start and stop dates, the dose or schedule if known, and whether the treatment was given alone or with other agents.
Next, record the biomarker context. If a test was done, name the test, the gene or protein examined, the result, and the date and laboratory. If no test was done, say so plainly. Do not guess a result or copy a figure from memory. A reviewer needs to know whether the targeted option was chosen because of a confirmed biomarker or for another reason.
Then describe the response in the terms your treating team used. 'Partial response on the scan in March' is more useful than 'it worked well'. If the response was stable disease, progression, or intolerance, use that wording. Include the reason for stopping: progression, toxicity, completion of planned cycles, cost, or patient choice. Finally, note what treatment, if any, is being given now and when the next assessment is due.
This structure is not a bureaucratic exercise. It is the difference between a reviewer being able to form a view and having to send the file back with questions.
What to send with the description
The written description should be supported by the source documents, not replace them. For each prior line, send the pathology report, the molecular or biomarker report if one exists, the imaging reports that document response, and the discharge or treatment summary. If a report is in another language, ask whether the receiving hospital needs a certified translation or accepts the original with an English summary.
Keep the first contact brief. An initial enquiry can start with a short summary and the patient's main question. The full archive can follow once the team confirms what it needs. Do not send passport numbers, payment details, or a complete medical archive through an initial article form.
If a document is missing, say which one and why. A missing biomarker report is different from a missing scan report, and the receiving clinician may be able to proceed with one but not the other. Ask what the centre requires rather than assuming a universal list.
Questions that decide whether the centre can assess the case
Before travelling, ask the hospital or coordination team a small set of specific questions. Can the centre review the previous treatment record and biomarker results remotely? Does it need the original slides or blocks for pathology review, or are reports sufficient? Which specialties would be involved if the case is complex?
Ask how ongoing treatment and monitoring would continue if the patient were accepted. Would the centre continue the current drug, switch to another targeted option, or recommend a different approach? What monitoring would be needed, and how often? These are clinical decisions for the treating team, but the patient can ask how the centre handles them.
Ask whether the specific drug or biomarker context is within the centre's experience. A centre may be strong in one tumour type and less familiar with another. This is not a judgement about quality; it is a practical matching question.
Finally, ask what the written plan or quote would include and exclude. Do not assume a component is included or charged separately. Ask the named provider about its actual scope.
Common ways the description goes wrong
The most frequent problem is naming a drug without its biomarker context. A reviewer cannot tell whether the drug was chosen for a molecular feature or for another reason. The second problem is describing response in vague terms such as 'it helped' or 'it stopped working' without the scan date or the treating team's wording.
A third problem is mixing lines together. If a patient received two drugs together, or switched from one to another, separate entries make the sequence clear. A fourth is omitting the reason for stopping. A drug stopped for toxicity tells a different story from one stopped for progression.
A fifth problem is sending a large file without a summary. A short structured summary at the front helps the reviewer find the relevant information quickly. It also shows that the patient has understood the question being asked.
A sixth problem is writing the record for the wrong audience. A description prepared for an insurance claim, a family member, or a personal diary often emphasises dates and costs while leaving out the biomarker result, the scan that documented response, and the reason the drug stopped. Those three items are exactly what a reviewing clinician needs, so a record that reads well to a relative may still be unusable for a clinical opinion.
A seventh problem is treating the record as a one-off task. Previous treatment results change as new scans are done, as a drug is stopped or restarted, and as a new line begins. A description written six months ago may no longer match the current situation. Reviewers need the most recent status, not only the history at the time of the first enquiry.
An eighth problem is over-interpreting the record. A patient may write that a drug 'failed' when the treating team documented stable disease, or describe a scan as showing progression when the report used different wording. Use the treating team's own terms and, where possible, quote the report. If the meaning is unclear, say so and ask the receiving clinician to interpret it rather than supplying your own conclusion.
A ninth problem is leaving out the practical context that affects whether treatment can continue. If a drug was stopped because it was unavailable, because of cost, or because the patient moved, that is different from stopping for progression or toxicity. Each reason points to a different question for the receiving centre, so state it plainly instead of leaving the reviewer to guess.
These problems are not about writing style. Each one removes a piece of information that a clinician would otherwise use to judge whether the case can be assessed and how ongoing treatment and monitoring might continue. Fixing them before sending the file reduces the number of clarification rounds and gives the receiving team a clearer basis for its own clinical judgement.
How to prepare and what to confirm next
Start by writing the structured entries for each previous treatment line. Use the patient's own records, not memory. Then collect the supporting reports and check whether any are missing. Write a short cover note stating the main question: for example, whether targeted therapy options remain and how treatment could continue in China.
Send a brief summary through the enquiry form, email, or WhatsApp. The team can check the available diagnosis, records, and the patient's main question, identify missing information, and suggest the relevant next step. This initial review is not a diagnosis or a promise of acceptance.
If a records-based specialist opinion is wanted before travel, a proxy consultation can be arranged, but it is optional and not a prerequisite for every appointment. The hospital decides suitability, and no review establishes that a particular drug is available or that treatment will be offered.
For urgent or worsening symptoms, seek local care first. An overseas enquiry should not delay necessary assessment. The practical next step is to prepare the structured treatment history and ask the centre what it needs to assess the case.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.